Eli Lilly Signs Significant Agreement with Seamless Therapeutics to Advance Gene Editing for Hearing Loss
Eli Lilly has entered a 1.12 billion dollar partnership with Seamless Therapeutics to develop hearing loss treatments. The deal focuses on gene-editing technology.
Insights:
Eli Lilly and Company announced on Wednesday it has signed an agreement worth up to $1.12 billion with Seamless Therapeutics to develop and commercialize treatments for hearing loss. This partnership provides Eli Lilly and Company, based in the 
US, with access to a proprietary gene-editing platform from the 
DE biotech firm to address genetic mutations linked to hearing impairment. Under the terms of the agreement, Eli Lilly and Companywill oversee the entire development process, beginning with preclinical testing and extending through to eventual commercialization.
US, with access to a proprietary gene-editing platform from the DE biotech firm to address genetic mutations linked to hearing impairment. Under the terms of the agreement, Eli Lilly and Companywill oversee the entire development process, beginning with preclinical testing and extending through to eventual commercialization.
